2013
Plasma Profiles of Matrix Metalloproteinases and Tissue Inhibitors of the Metalloproteinases Predict Recurrence of Atrial Fibrillation Following Cardioversion
Mukherjee R, Akar JG, Wharton JM, Adams DK, McClure CD, Stroud RE, Rice AD, DeSantis SM, Spinale FG, Gold MR. Plasma Profiles of Matrix Metalloproteinases and Tissue Inhibitors of the Metalloproteinases Predict Recurrence of Atrial Fibrillation Following Cardioversion. Journal Of Cardiovascular Translational Research 2013, 6: 528-535. PMID: 23722357, DOI: 10.1007/s12265-013-9471-2.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationBiomarkersChi-Square DistributionC-Reactive ProteinElectric CountershockFibrosisHeart AtriaHumansLogistic ModelsMatrix MetalloproteinasesMiddle AgedMultivariate AnalysisNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsRecurrenceRisk FactorsTime FactorsTissue Inhibitor of MetalloproteinasesTreatment OutcomeConceptsAF recurrenceMatrix metalloproteinasesMMP-9TIMP-4MMP-3N-terminus pro B type natriuretic peptideHigh-sensitivity C-reactive protein levelsPro-B-type natriuretic peptideTissue inhibitorC-reactive protein levelsB-type natriuretic peptideLevels of MMPsAtrial fibrillation recurrenceNovel biomarker panelAtrial volumeNatriuretic peptideAtrial fibrosisSinus rhythmPredicts RecurrenceBiomarker panelRecurrenceMultivariate analysisPostcardioversionProtein levelsPlasma samples
2012
2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design
Calkins H, Hindricks G, Cappato R, Kim Y, Saad E, Aguinaga L, Akar J, Badhwar V, Brugada J, Camm J, Chen P, Chen S, Chung M, Nielsen J, Curtis A, Davies D, Day J, d’Avila A, de Groot N, Di Biase L, Duytschaever M, Edgerton J, Ellenbogen K, Ellinor P, Ernst S, Fenelon G, Gerstenfeld E, Haines D, Haissaguerre M, Helm R, Hylek E, Jackman W, Jalife J, Kalman J, Kautzner J, Kottkamp H, Kuck K, Kumagai K, Lee R, Lewalter T, Lindsay B, Macle L, Mansour M, Marchlinski F, Michaud G, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds M, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao H, Verma A, Wilber D, Yamane T. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Heart Rhythm 2012, 9: 632-696.e21. PMID: 22386883, PMCID: PMC5846182, DOI: 10.1016/j.hrthm.2011.12.016.Peer-Reviewed Original Research
2001
Coexistence of type I atrial flutter and intra-atrial re-entrant tachycardia in patients with surgically corrected congenital heart disease
Akar J, Kok L, Haines D, DiMarco J, Mounsey J. Coexistence of type I atrial flutter and intra-atrial re-entrant tachycardia in patients with surgically corrected congenital heart disease. Journal Of The American College Of Cardiology 2001, 38: 377-384. PMID: 11499727, DOI: 10.1016/s0735-1097(01)01392-4.Peer-Reviewed Original ResearchConceptsIntra-atrial re-entrant tachycardiaIsthmus-dependent atrial flutterCongenital heart diseaseRe-entrant tachycardiaAtrial flutterHeart diseaseType I atrial flutterSurface electrocardiogramInferior vena cavaSlow conduction zoneRe-entrant tachyarrhythmiasLateral right atriumAtriotomy scarCoexistent arrhythmiaIART recurrenceConsecutive patientsAtrial tachyarrhythmiasProcedural complicationsSupraventricular tachyarrhythmiasFurther recurrenceSuccessful ablationRight atriumVena cavaSurgical correctionEntrainment mapping